Shanghai Xuerong BiotechnologyLtd Management

Management criteria checks 2/4

Shanghai Xuerong BiotechnologyLtd's CEO is Yongping Yang, appointed in Apr 2022, has a tenure of 2.58 years. directly owns 21.57% of the company’s shares, worth CN¥427.20M. The average tenure of the management team and the board of directors is 2.6 years and 1.9 years respectively.

Key information

Yongping Yang

Chief executive officer

CN¥1.0m

Total compensation

CEO salary percentage	n/a
CEO tenure	2.6yrs
CEO ownership	21.6%
Management average tenure	2.6yrs
Board average tenure	1.9yrs

Recent management updates

Recent updates

CEO

Yongping Yang (55 yo)

2.6yrs

Tenure

CN¥1,026,600

Compensation

Mr. Yongping Yang serves as Chairman of Shanghai Xuerong Bio-Technology Co., Ltd. and serves as its General Manager since April 12, 2022. Mr. Yang serves as Honorary President of Fujian Chamber of Commerce...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yongping Yang	Chairman & GM	2.6yrs	CN¥1.03m	21.57% CN¥ 427.2m
Yong Lu	Deputy GM & Non-Independent Director	no data	CN¥845.30k	no data
Wei Guo	Deputy GM & Non-Independent Director	2.6yrs	CN¥1.01m	0.012% CN¥ 238.2k
Yongkang Gu	Board Secretary	5.9yrs	CN¥717.00k	0.0059% CN¥ 116.0k

2.6yrs

Average Tenure

48.5yo

Average Age

Experienced Management: 300511's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yongping Yang	Chairman & GM	no data	CN¥1.03m	21.57% CN¥ 427.2m
Yong Lu	Deputy GM & Non-Independent Director	2.5yrs	CN¥845.30k	no data
Wei Guo	Deputy GM & Non-Independent Director	1.9yrs	CN¥1.01m	0.012% CN¥ 238.2k
Lihua Mao	Non-Employee Supervisor	7.3yrs	no data	no data
Jianchun Huang	Independent Director	4yrs	CN¥120.00k	no data
Jie Li	Director	1.7yrs	CN¥773.50k	0.0096% CN¥ 190.5k
Xueyao Li	Independent Director	1.5yrs	CN¥120.00k	no data
Danmeng Li	Independent Director	1.3yrs	CN¥42.60k	no data

1.9yrs

Average Tenure

49.5yo

Average Age

Experienced Board: 300511's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Shanghai Xuerong BiotechnologyLtd Management

Management criteria checks 2/4

Key information

Recent management updates

High number of new directors

Shanghai Xuerong Biotechnology Co.,Ltd., Annual General Meeting, May 17, 2024

Shanghai Xuerong Biotechnology Co.,Ltd. Approves Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Shanghai Xuerong Biotechnology Co.,Ltd. Approves By-Election of Directors

Recent updates

Third quarter 2024 earnings released: CN¥0.041 loss per share (vs CN¥0.38 loss in 3Q 2023)

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: CN¥0.32 loss per share (vs CN¥0.34 loss in 2Q 2023)

Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511) agreed to acquire remaining 31.03% stake in Lintao Xuerong Biotechnology Co., Ltd. from Gansu Green and Ecological Industry Development Government Guided Fund Management Co., Ltd. for approximately CNY 45 million.

High number of new directors

Shanghai Xuerong Biotechnology Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

Shanghai Xuerong Biotechnology Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.45 in 1Q 2023)

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New major risk - Financial position

Third quarter 2023 earnings released: CN¥0.38 loss per share (vs CN¥0.12 profit in 3Q 2022)

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

Second quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥0.30 loss in 2Q 2022)

Shanghai Xuerong Biotechnology Co.,Ltd. Approves Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.11 loss in 3Q 2021)

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.11 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.30 loss per share (vs CN¥0.37 loss in 2Q 2021)

Shanghai Xuerong Biotechnology Co.,Ltd. Approves By-Election of Directors

Shanghai Xuerong Biotechnology Co.,Ltd. Announces Final Cash Dividend Proposal for 2021

First quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.24 in 1Q 2021)

Now 21% undervalued

Second quarter 2021 earnings released: CN¥0.37 loss per share (vs CN¥0.033 loss in 2Q 2020)

Shanghai Xuerong Biotechnology Co.,Ltd. Announces to Implement Final Cash Distribution Plan for 2020, Payable on 14 May 2021

Shanghai Xuerong Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.40 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.57 (vs CN¥0.51 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥10.82

New 90-day low: CN¥12.17

New 90-day low: CN¥13.30

New 90-day low: CN¥13.81

New 90-day low: CN¥14.39

Shanghai Xuerong Biotechnology Co.,Ltd. announced that it expects to receive CNY 2.25 billion in funding

Third quarter earnings released

First half earnings released

New 90-day high - CN¥19.22

Shanghai Xuerong Biotechnology Co.,Ltd. to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥18.35

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age